These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24394380)

  • 21. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
    Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J
    Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry.
    La Manna A; Miccichè E; D'Agosta G; Tensol Rodrigues Pereira G; Attizzani GF; Capranzano P; Capodanno D; Tamburino C
    Int J Cardiol; 2018 Feb; 253():45-49. PubMed ID: 29137819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
    Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW
    Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions: Impact of polymeric wide struts on side-branch impairment.
    De Paolis M; Felix C; van Ditzhuijzen N; Fam JM; Karanasos A; de Boer S; van Mieghem NM; Daemen J; Costa F; Bergoli LC; Ligthart JM; Regar E; de Jaegere PP; Zijlstra F; van Geuns RJ; Diletti R
    Int J Cardiol; 2016 Oct; 221():656-64. PubMed ID: 27423087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion.
    Wiebe J; Liebetrau C; Dörr O; Most A; Weipert K; Rixe J; Bauer T; Möllmann H; Elsässer A; Hamm CW; Nef HM
    Int J Cardiol; 2015 Jan; 179():90-4. PubMed ID: 25464422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-endothelialisation after Synergy stent and Absorb bioresorbable vascular scaffold implantation in acute myocardial infarction: COVER-AMI study.
    Lhermusier T; Ohayon P; Boudou N; Bouisset F; Campelo-Parada F; Roncalli J; Elbaz M; Carrié D
    Trials; 2019 Apr; 20(1):210. PubMed ID: 30975219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography.
    Gonzalo N; Barlis P; Serruys PW; Garcia-Garcia HM; Onuma Y; Ligthart J; Regar E
    JACC Cardiovasc Interv; 2009 May; 2(5):445-52. PubMed ID: 19463469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography.
    Gomez-Lara J; Radu M; Brugaletta S; Farooq V; Diletti R; Onuma Y; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Sep; 4(9):992-1001. PubMed ID: 21939939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry).
    Ielasi A; Cortese B; Varricchio A; Tespili M; Sesana M; Pisano F; Loi B; Granata F; Moscarella E; Silva Orrego P; La Vecchia L; Steffenino G;
    EuroIntervention; 2015 Jun; 11(2):157-62. PubMed ID: 25354760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Third-Generation Sirolimus-Eluting Bioresorbable Tyrocore Scaffold Implantation in Patients with ST-Segment Elevation Myocardial Infarction: Baseline and 6-Month OCT and Clinical Outcomes-a FANTOM STEMI Pilot Study.
    Koltowski L; Tomaniak M; Ochijewicz D; Opolski G; Kochman J
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):719-729. PubMed ID: 36640215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study.
    Widimsky P; Petr R; Tousek P; Maly M; Linkova H; Vrana J; Hajsl M; Budesinsky T; Lisa L; Kocka V
    Circ Cardiovasc Interv; 2015 Dec; 8(12):e002933. PubMed ID: 26628591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
    Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
    Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold.
    Karanasos A; Simsek C; Gnanadesigan M; van Ditzhuijzen NS; Freire R; Dijkstra J; Tu S; Van Mieghem N; van Soest G; de Jaegere P; Serruys PW; Zijlstra F; van Geuns RJ; Regar E
    J Am Coll Cardiol; 2014 Dec; 64(22):2343-56. PubMed ID: 25465421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update.
    Toušek P; Kočka V; Malý M; Kozel M; Petr R; Hajsl M; Jarkovský J; Lisa L; Buděšínský T; Widimský P
    EuroIntervention; 2016 May; 12(1):23-9. PubMed ID: 27173858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
    de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
    Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serial Baseline, 12-, 24-, and 60-Month Optical Coherence Tomography Evaluation of ST Segment Elevation Myocardial Infarction Patients Treated with Absorb Bioresorbable Vascular Scaffold.
    Koltowski L; Tomaniak M; Ochijewicz D; Zieliński K; Proniewska K; Malinowski KP; Zaleska M; Maksym J; Roleder T; Partyka L; Kochman W; Filipiak KJ; Opolski G; Kochman J
    Am J Cardiol; 2021 Sep; 155():23-31. PubMed ID: 34315572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.